<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23640393</article-id><article-id pub-id-type="pmc">3671094</article-id><article-id pub-id-type="pii">bjc2013179</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery <italic>vs</italic> radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)</article-title><alt-title alt-title-type="running">Phase III trial of NACT plus RS <italic>vs</italic> RS alone in cervical cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Katsumata</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Yoshikawa</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kuzuya</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nakanishi</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Yasugi</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Yaegashi</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yokota</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kodama</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Mizunoe</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Hiura</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Kasamatsu</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Kamura</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><on-behalf-of>on behalf of the Japan Clinical Oncology Group</on-behalf-of><aff id="aff1"><label>1</label><institution>Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital</institution>, Kawasaki, <country>Japan</country></aff><aff id="aff2"><label>2</label><institution>Department of Obstetrics and Gynecology, University of Tsukuba</institution>, Tsukuba, <country>Japan</country></aff><aff id="aff3"><label>3</label><institution>Department of Obstetrics and Gynecology, Kyushu University</institution>, Fukuoka, <country>Japan</country></aff><aff id="aff4"><label>4</label><institution>Department of Gynecologic Oncology, Kyushu Cancer Center</institution>, Fukuoka, <country>Japan</country></aff><aff id="aff5"><label>5</label><institution>Kuzuya Clinic</institution>, Nagoya, <country>Japan</country></aff><aff id="aff6"><label>6</label><institution>Department of Gynecologic Oncology, Aichi Cancer Center</institution>, Nagoya, <country>Japan</country></aff><aff id="aff7"><label>7</label><institution>Department of Obstetrics and Gynecology, Tokyo University</institution>, Tokyo, <country>Japan</country></aff><aff id="aff8"><label>8</label><institution>Department of Obstetrics and Gynecology, Tohoku University</institution>, Sendai, <country>Japan</country></aff><aff id="aff9"><label>9</label><institution>Department of Gynecologic Oncology, Saitama Cancer Center</institution>, Saitama, <country>Japan</country></aff><aff id="aff10"><label>10</label><institution>Department of Gynecologic Oncology, Niigata Cancer Center</institution>, Niigata, <country>Japan</country></aff><aff id="aff11"><label>11</label><institution>Department of Gynecologic Oncology, Kure Medical Center</institution>, Kure, <country>Japan</country></aff><aff id="aff12"><label>12</label><institution>Department of Gynecologic Oncology, Shikoku Cancer Center</institution>, Matsuyama, <country>Japan</country></aff><aff id="aff13"><label>13</label><institution>Department of Gynecologic Oncology, National Cancer Center Hospital</institution>, Tokyo, <country>Japan</country></aff><aff id="aff14"><label>14</label><institution>Japan Clinical Oncology Group Data Center, Multi-institutional Clinical Trial Support Center, National Cancer Center</institution>, Tokyo, <country>Japan</country></aff><aff id="aff15"><label>15</label><institution>Department of Obstetrics and Gynecology, Kurume University</institution>, Kurume, <country>Japan</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>nkatsuma@nms.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><day>28</day><month>05</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>02</day><month>05</month><year>2013</year></pub-date><volume>108</volume><issue>10</issue><fpage>1957</fpage><lpage>1963</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2012</year></date><date date-type="rev-recd"><day>17</day><month>03</month><year>2013</year></date><date date-type="accepted"><day>01</day><month>04</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title>Background:</title><p>A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival.</p></sec><sec><title>Methods:</title><p>Patients with stage IB2, IIA2, or IIB squamous cell carcinoma of the uterine cervix were randomly assigned to receive either BOMP (bleomycin 7&#x02009;mg days 1&#x02013;5, vincristine 0.7&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> day 5, mitomycin 7&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> day 5, cisplatin 14&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> days 1&#x02013;5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group) or RS alone (RS group). Patients with pathological high-risk factors received postoperative radiotherapy (RT). The primary end point was overall survival.</p></sec><sec><title>Results:</title><p>A total of 134 patients were randomly assigned to treatment. This study was prematurely terminated at the first planned interim analysis because overall survival in the NACT group was inferior to that in the RS group. Patients who received postoperative RT were significantly lower in the NACT group (58&#x00025;) than in the RS group (80&#x00025; <italic>P</italic>=0.015). The 5-year overall survival was 70.0&#x00025; in the NACT group and 74.4&#x00025; in the RS group (<italic>P</italic>=0.85).</p></sec><sec><title>Conclusion:</title><p>Neoadjuvant chemotherapy with BOMP regimen before RS did not improve overall survival, but reduced the number of patients who received postoperative RT.</p></sec></abstract><kwd-group><kwd>cervical cancer</kwd><kwd>neoadjuvant chemotherapy</kwd><kwd>phase III trial</kwd><kwd>radical surgery</kwd></kwd-group></article-meta></front><body><p>Treatment of International Federation of Gynaecology and Obstetrics (FIGO) stages IB2, IIA2, and IIB cervical cancer remains controversial. Bulky stage IIA (tumour diameter &#x0003e;4&#x02009;cm) cervical cancer was revised to stage IIA2 (<xref ref-type="bibr" rid="bib18">Pecorelli <italic>et al</italic>, 2009</xref>) in the FIGO staging system in 2009. Major treatment options include radical surgery (RS) with or without postoperative radiotherapy (RT), neoadjuvant chemotherapy (NACT) followed by RS with or without postoperative RT, and concurrent chemoradiotherapy (CCRT). Radical surgery usually entails type III radical hysterectomy (<xref ref-type="bibr" rid="bib20">Piver <italic>et al</italic>, 1974</xref>) plus pelvic or para-aortic lymphadenectomy (or both). For stage IB2 and IIA2 cervical cancer, the National Comprehensive Cancer Network (<xref ref-type="bibr" rid="bib13">NCCN Clinical Practice Guidelines, 2012</xref>) clinical guidelines mainly recommend CCRT (category 1) and, to a lesser degree, radical hysterectomy with pelvic lymphadenectomy and para-aortic lymph node sampling (category 2b). In Japan, however, more radical procedures, such as Okabayashi's (type III or IV) radical hysterectomy plus pelvic or para-aortic lymphadenectomy (or both), remain the standard treatment of choice for stages IB2, IIA2, and IIB cervical cancer (<xref ref-type="bibr" rid="bib6">Fujii <italic>et al</italic>, 2007</xref>).</p><p>Before we started this study, only one randomised controlled trial conducted at a single centre had compared NACT plus RS with RS alone. In 1997, <xref ref-type="bibr" rid="bib22">Sardi <italic>et al</italic> (1997</xref>) reported the results of a randomised trial that compared NACT plus RS with RS in 205 patients with stages IB squamous cell cervical cancer. Three courses of NACT with vincristine, bleomycin, and cisplatin (VBP) were given in NACT group. Overall survival at 8 years with NACT group was superior to RS group (81&#x00025; <italic>vs</italic> 66&#x00025;, <italic>P</italic>&#x0003c;0.05). In a subgroup analysis in patients with non-bulky tumours &#x0003c;4&#x02009;cm, there was no significant difference between the two groups (82&#x00025; <italic>vs</italic> 77&#x00025;, NS).</p><p>Thus, NACT plus RS has emerged as a valid alternative investigational treatment. In 1998, one institution affiliated with our group confirmed that combination chemotherapy with bleomycin, vincristine, mitomycin, and cisplatin (BOMP) produced a high response rate (76&#x00025;) in metastatic cervical cancer (<xref ref-type="bibr" rid="bib24">Shimizu <italic>et al</italic>, 1998</xref>). We decided to use the BOMP regimen as NACT.</p><p>To clarify the potential benefits of NACT before RS, we undertook a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2, IIA2, and IIB cervical cancer.</p><sec sec-type="methods"><title>Patients and methods</title><sec><title>Eligibility criteria</title><p>Patients who had primary, previously untreated, histologically confirmed squamous cell carcinoma of the cervix with bulky FIGO stage IB2, IIA, and IIB disease (tumour diameter &#x0003e;4&#x02009;cm on magnetic resonance imaging (MRI)) were eligible for this Japan Clinical Oncology Group (JCOG) study (JCOG 0102). In July 2003, the criteria were amended to patients with FIGO stage IB2, IIA2 (tumour diameter &#x0003e;4&#x02009;cm by clinical measurement), and IIB (irrespective of tumour diameter) disease and additionally required the presence of target cervical lesions (&#x0003e;2&#x02009;cm) on MRI according to the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines. Patients who were suitable candidates for radical hysterectomy as described in the treatment schedule section were eligible. Patients were also required to be between 20 and 70 years of age, to have performance status of 0 or 1, and to have normal organ functions and normal electrocardiogram. Patients with any of the following conditions were excluded: synchronous or metachronous (within 5 years) malignancy other than carcinoma <italic>in situ</italic> or mucosal cancer; pregnancy; psychotic disease; active infection with fever; uncontrolled hypertension or diabetes mellitus; positive hepatitis B surface antigen; a history of heart failure, unstable angina, or myocardial infarction; interstitial pneumonitis or pulmonary fibrosis; or severe obesity, liver cirrhosis, or bleeding tendency. All patients gave informed consent before enrolment in this study, which was approved by the institutional review boards at the participating institutions (UMIN-CTR No. C000000194 and clinicaltrials.gov No. NCT00190528).</p></sec><sec><title>Treatment schedule</title><sec><title>Neoadjuvant chemotherapy</title><p>Patients were randomly assigned to receive either NACT followed by RS or RS alone. The BOMP regimen for NACT comprised bleomycin (7&#x02009;mg) as a 30-min intravenous infusion on days 1&#x02013;5, vincristine (0.7&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) as a bolus intravenous injection on day 5, mitomycin (7&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) as a bolus intravenous injection on day 5, and cisplatin (14&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) as a 30-min intravenous infusion on days 1&#x02013;5 of a 21-day cycle. Patients initially received two cycles. Patients who had a complete response (CR) or partial response (PR) after two cycles of BOMP were given two additional cycles. Treatment was administered if the white cell count was &#x02a7e;2000 per <italic>&#x003bc;</italic>l and the platelet count was &#x02a7e;75&#x02009;000 per <italic>&#x003bc;</italic>l. Treatment could be delayed for up to 2 weeks until these minimum criteria were met.</p><p>After NACT, the patients were clinically reassessed and classified as suitable or unsuitable for radical hysterectomy. The criteria for radical hysterectomy includes adequate organ function with good performance status. The unsuitable patients received RT, including whole pelvis RT and brachytherapy.</p></sec><sec><title>Surgery</title><p>The standard procedure used to perform radical hysterectomy in this study was based on Okabayashi's radical hysterectomy as reported by Kyoto Imperial University in 1921. This procedure involves wide extirpation of the parametrial tissue and separation of the posterior leaf of the vesicouterine ligament (<xref ref-type="bibr" rid="bib16">Okabayashi, 1921</xref>). With the use of this technique, the surgeon can separate the bladder with the ureter completely away from the lateral side of the cervix and the vagina. This dissection facilitates resection of all periureteral tissue and any length (more than one-third) of the vagina and paravaginal tissues. Okabayashi's radical hysterectomy is thus classified as type III or IV radical hysterectomy (<xref ref-type="bibr" rid="bib16">Okabayashi, 1921</xref>).</p><p>In this study, radical hysterectomy require removal of at least 3&#x02009;cm of the vaginal and paravaginal tissues, and if the vagina was involved, removal of the vagina and vaginal tissues with a margin of at least 2&#x02009;cm from the cancer. Twenty or more pelvic lymph nodes were required to dissect. If metastases to the para-aortic nodes were suspected, the para-aortic nodes were sampled or dissected. Radical surgery was performed within 3 weeks after randomisation in the RS group and within 8 weeks after the last administration of chemotherapy in the NACT group.</p></sec><sec><title>Postoperative RT</title><p>The protocol required that postoperative RT was started within 6 weeks after surgery. A total dose of 4500&#x02013;5040&#x02009;cGy was delivered to the whole pelvis in daily fractions of 180&#x02013;200&#x02009;cGy if patients had pelvic lymph node metastasis, parametrial involvement, or deep stromal invasion (&#x02a7e;2/3). Extended-field external beam therapy, delivering a dose of 4500&#x02009;cGy by a four-field technique, was administered to patients with positive para-aortic nodes. High-dose rate brachytherapy was delivered to the vaginal stump if patients had positive surgical margins.</p></sec><sec><title>Response and toxicity evaluation</title><p>Tumour response in the NAC group was assessed according to the RECIST guidelines (<xref ref-type="bibr" rid="bib26">Therasse <italic>et al</italic>, 2000</xref>). Target lesions, including the primary cervical tumour, were measured by MRI. An independent response review committee evaluated all tumour responses after the investigators had completed their assessments.</p><p>Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 2.0) (<xref ref-type="bibr" rid="bib27">Trotti <italic>et al</italic>, 2000</xref>). Surgical morbidity was defined as adverse events related to surgery that occurred between the date of surgery 1 month postoperatively. Early and late adverse events of RT were respectively defined as adverse events that occurred within the first 90 days or more than 90 days after the completion of RT. Late adverse events were evaluated according to the RTOG/EORTC Late Radiation Morbidity Scoring Scheme in <xref ref-type="app" rid="app1">Appendix</xref> IV of NCI-CTC, version 2.0 (<xref ref-type="bibr" rid="bib27">Trotti <italic>et al</italic>, 2000</xref>).</p></sec><sec><title>Statistical considerations</title><p>This was a randomised, multicentre, nonblinded, prospective, phase III study. After confirmation of the inclusion/exclusion criteria by telephone or fax to the JCOG Data Center, the patients were randomly assigned to treatment according to a minimisation procedure. Minimisation criteria were disease stage (I; II), age (&#x02a7d;50 years; &#x0003e;50 years), and institution. The primary end point was overall survival. The secondary end points were progression-free survival, surgical morbidity, compliance with radical hysterectomy, omission of postoperative irradiation, early and late radiation-related morbidity, and rate of response to chemotherapy. Overall survival was measured from the date of registration to the date of death from any cause, and data were censored at the time of the last follow-up for surviving patients. Progression-free survival was measured from the date of randomisation to the date of the first event (i.e., confirmation of disease progression or death from any cause), and data were censored at the last date on which the absence of disease progression was confirmed.</p><p>We assumed that the 5-year survival rate would be 60&#x00025; in the RS group and 75&#x00025; in the NACT group. The planned sample size was 100 patients in each treatment group, with a one-sided <italic>&#x003b1;</italic>-level of 0.05, a power of 0.8, an accrual of 5.5 years, and a follow-up of 3.5 years (<xref ref-type="bibr" rid="bib23">Schoenfeld and Richter, 1982</xref>). Two interim analyses were scheduled. The first interim analysis was done when 100 patients had been randomly assigned to treatment, and the second was done when all patients had been assigned treatment. Multiplicity was adjusted by the method proposed by the Southwest Oncology Group (<xref ref-type="bibr" rid="bib7">Green <italic>et al</italic>, 1997</xref>). The significant levels were one-sided 0.005 at each interim analysis and one-sided 0.045 at the final analysis. Survival curves were estimated with the Kaplan&#x02013;Meier method, and stratified log-rank tests were used to assess differences between treatment groups, stratified according to disease stage (I <italic>vs</italic> II) and age (&#x02a7d;50 years <italic>vs</italic> &#x0003e;50 years). We used a Cox proportional hazard model to estimate treatment effects. All analyses were done on an intention-to-treat basis, except for toxicity. Toxicity analyses were restricted to patients who had received at any part of their assigned treatment. Although this trial was designed for one-sided hypothesis testing, follow-up results are reported with two-sided <italic>P</italic>-values because of the exploratory nature of the analysis. All analyses were carried out using SAS software, version 9.1 (SAS Institute, Cary, NC, USA).</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>Enrolment in this study began on 1 December 2001. The first planned interim analysis was performed in July 2005 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Data from 108 patients enrolled by November 2004 were analysed. On the basis of this analysis, the Data and Safety Monitoring Committee (DSMC) recommended to prematurely terminate the study because overall survival in the NACT group was inferior to that in the RS group (HR, 2.11; multiplicity-adjusted 99&#x00025; CI, 0.34&#x02013;13.2), and the predicted probability of significant superiority in the NACT group at the end of the study as assessed by Spiegelhalter's method (<xref ref-type="bibr" rid="bib25">Spiegelhalter <italic>et al</italic>, 1993</xref>) was extremely low (6.4&#x00025;). The study was therefore closed on 1 August 2005.</p><p>Between December 2001 and August 2005, a total of 134 patients (67 in the NACT group and 67 in the RS group) were randomly assigned to treatment at 28 institutions. <xref rid="tbl1" ref-type="table">Table 1</xref> summarises the baseline characteristics of the patients. One patient in the RS group was ineligible because of an incorrect histopathological diagnosis of adenosquamous carcinoma on cervical biopsy before enrolment. Three patients in the NACT group who were given a diagnosis of squamous cell carcinoma on biopsy before enrolment were found to have adenosquamous carcinoma on evaluation of their surgical specimens. These patients were considered eligible.</p><p>Of the 67 patients randomly assigned to the NACT group, 66 received chemotherapy. One patient did not receive chemotherapy because of her refusal after registration. This patient underwent primary RS. The other 66 patients received at least two cycles of NACT. The overall response (CR&#x0002b;PR) rate was 70&#x00025; (47 out of 67) on the investigators' assessment and 66&#x00025; (44 out of 67) on independent central review (<xref rid="tbl2" ref-type="table">Table 2</xref>). Toxicity associated with chemotherapy is summarised in <xref rid="tbl3" ref-type="table">Table 3</xref>. Nearly all toxic effects were tolerable, and chemotherapy could be continued in all but three patients who discontinued treatment during the third or fourth cycle because of toxicity (persistent grade 3 thrombocytopenia in two patients and grade 3 skin toxicity in one patient). Grade 3 alkalosis with hypertension, thrombosis, atrial fibrillation, or skin ulceration occurred in one patient each, but these toxic effects were transient and soon resolved.</p><p>Of the 67 patients in each group, 62 (93&#x00025;) underwent RS, suggesting that operability was similar in the groups. Five patients in the RS group and one in the NACT group underwent laparotomy for RS, but the procedure was terminated during surgery because of inoperable disease associated with conditions such as pelvic wall involvement, disseminated tumours, or both. Median dissected lymph nodes were 47 (range 20&#x02013;119) in the RS group and 45 (range 13&#x02013;95) in the NACT group. Para-aortic lymph node sampling and dissection were respectively performed in 22 and 14 patients in the RS group and 20 and 14 patients in the NACT group. Median blood loss and operation time were respectively 950&#x02009;ml and 5.5&#x02009;h in the RS group and 1370&#x02009;ml and 5.6&#x02009;h in the NACT group.</p><p><xref rid="tbl4" ref-type="table">Table 4</xref> shows the pathological findings of surgical specimens obtained from patients who underwent RS. The median tumour diameter in the NACT group was smaller than that in the RS group (3.0 <italic>vs</italic> 5.1&#x02009;cm). On postsurgical T classification (pT), downstaging to pT0-Ib1 was confirmed in 40&#x00025; of the patients in the NACT group. The proportion of patients with positive pelvic nodes was lower but statistically not significant in the NACT group than in the RS group (27&#x00025; <italic>vs</italic> 44&#x00025;, <italic>P</italic>=0.091), whereas parametrial involvement was similar in both groups (40&#x00025; <italic>vs</italic> 45&#x00025;, <italic>P</italic>=0.717). The incidence of para-aortic lymph node metastasis was 2 and 1 in the RS group and NACT group, respectively.</p><p>As for surgical morbidity, ureteral or bladder injuries occurred and were repaired during surgery in two patients in the RS group and two in the NACT group. A ureterovaginal fistula developed postoperatively in another patient in the RS group. Grade 3 wound infections occurred in one patient in the RS group and two patients in the NACT group. Grade 3 dysuria developed in one patient in the RS group. Grade 3 disseminated intravascular coagulation occurred in one patient in the NACT group. The incidences of pneumonia, bowel obstruction, and haemorrhage during the first month after surgery were similar in both treatment groups (0, 3, and 0 patients in the RS group <italic>vs</italic> 1, 2, and 1 patients in the NACT group).</p><p>The proportion of patients who met the criteria for postoperative radiation (i.e., lymph node metastasis, parametrial involvement, or deep stromal invasion &#x0003e;2/3) was significantly lower in the NACT group (48 (72&#x00025;) of 67) than in the RS group (59 (89&#x00025;) of 66; <italic>P</italic>=0.015), and the patients who received radiation in the NACT group (39 (58&#x00025;) of 67) were lower than those in the RS group (53 (79&#x00025;) of 67; <italic>P</italic>=0.015). Postoperative RT to the whole pelvis, RT to the para-aortic region, and brachytherapy were respectively given to 53, 2, and 5 patients in the RS group and 38, 3, and 4 patients in the NACT group. Early adverse events (within 90 days after radiation) occurred in 70&#x00025; (46 of 66) of the patients in the RS group and 55&#x00025; (37 of 67; <italic>P</italic>=0.108) of the patients in the NACT group. Grade 3 or 4 haematologic toxicity was more common in the NACT group than in the RS group (<xref rid="tbl5" ref-type="table">Table 5</xref>), whereas nonhaematologic toxic effects such as diarrhoea or urinary retention were more common in the RS group than in the NACT group. Late adverse events (90 days or more after radiation) occurred in 65&#x00025; (43 of 66) of the patients in the RS group and 42&#x00025; (28 of 67; <italic>P</italic>=0.009) of the patients in the NACT group. The incidence of grade 3 or 4 lymphedema was slightly higher in the NACT group than in the RS group, whereas urinary retention and bowel obstruction were more common in the RS group than in the NACT group. One patient in the NACT group died of perforation and necrosis of the small intestine 215 days after the last dose of radiation. This death was considered treatment related.</p><p>At the time of final follow-up (May 2008), with a median follow-up of 49 months for patients with censored data, there had been 17 deaths in the NACT group and 16 in the RS group. The 5-year overall survival was 70.0&#x00025; in the NACT group and 74.4&#x00025; in the RS group (<xref ref-type="fig" rid="fig2">Figure 2</xref>; hazard ratio (HR) by Cox regression analysis, 1.07; 95&#x00025; CI, 0.54&#x02013;2.12; two-sided <italic>P</italic>=0.85, stratified log-rank test). The 5-year progression-free survival was 59.9&#x00025; in the NACT group and 62.7&#x00025; in the RS group (<xref ref-type="fig" rid="fig2">Figure 2</xref>; HR, 1.06; 95&#x00025; CI, 0.60&#x02013;1.88; two-sided <italic>P</italic>=0.85, stratified log-rank test). On subgroup analyses among patients with stage IB2 disease, the 5-year overall survival and progression-free survival were, respectively, 82.9&#x00025; and 71.2&#x00025; in the RS group (<italic>n</italic>=25) and 78.4&#x00025; and 60.5&#x00025; in the NACT group (<italic>n</italic>=25), and among patients with stages IIA2 and IIB disease, the 5-year overall survival and progression-free survival were 69.5&#x00025; and 58.4&#x00025; in the RS group (<italic>n</italic>=42) and 65.3&#x00025; and 59.3&#x00025; in the NACT group (<italic>n</italic>=42).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Our study concluded that NACT with BOMP before RS did not improve overall survival of patients with stages IB2, IIA2, and IIB cervical cancer. However, NACT was associated with a reduced proportion of patients who received postoperative RT.</p><p>The benefits of NACT followed by surgery as compared with surgery alone were addressed in a Cochrane meta-analysis (<xref ref-type="bibr" rid="bib21">Rydzewska <italic>et al</italic>, 2010</xref>) of six phase III trials (FIGO stage of the subjects: Sardi's trial (<xref ref-type="bibr" rid="bib22">Sardi <italic>et al</italic>, 1997</xref>), IB1&#x0002b;IB2; Napolitano's trial (<xref ref-type="bibr" rid="bib12">Napolitano <italic>et al</italic>, 2003</xref>), IB-IIIB; Cai's trial (<xref ref-type="bibr" rid="bib2">Cai <italic>et al</italic>, 2006</xref>), IB1&#x0002b;IB2; Katsumata's trial (present study) (<xref ref-type="bibr" rid="bib8">Katsumata <italic>et al</italic>, 2006</xref>), IB2, IIA2, IIB; Eddy's trial (<xref ref-type="bibr" rid="bib4">Eddy <italic>et al</italic>, 2007</xref>), IB2; Chen's trial (<xref ref-type="bibr" rid="bib3">Chen <italic>et al</italic>, 2008</xref>), IB2-IIB) of 1036 patients, including our immature survival data, after a median follow-up of 34 months. Progression-free survival was significantly improved by NACT&#x0002b;RS (HR=0.76, 95&#x00025; CI, 0.62&#x02013;0.94). However, the improvement in overall survival with NACT plus RS was not statistically significant (HR=0.85, 95&#x00025; CI, 0.67&#x02013;1.07). Only Sardi's trial showed a statistically significant benefit of NACT in terms of overall survival (HR=0.53, 95&#x00025; CI, 0.31&#x02013;0.92) (<xref ref-type="bibr" rid="bib22">Sardi <italic>et al</italic>, 1997</xref>). Among the six trials, Eddy's GOG trial (<xref ref-type="bibr" rid="bib4">Eddy <italic>et al</italic>, 2007</xref>) and our trial demonstrated no survival benefit of NACT (HR=1.01, 95&#x00025; CI, 0.68&#x02013;1.49 and HR=1.12, 95&#x00025; CI, 0.56&#x02013;2.22). Why the results differed substantially among trials remains unclear. The meta-analysis concluded that the type of drugs used or how they were given had no effect on the overall results. Moreover, the results were similar in women with early-stage disease and those with more advanced cancer.</p><p>The clinical response rate of 67&#x00025; reported in this study is lower than the rate of 84&#x00025; obtained in patients with stage IB2 disease in Sardi's trial (quick VBP regimen: intravenous vincristine 1&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, bleomycin 25&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on days 1&#x02013;3 and cisplatin 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> every 10 days for 3 cycles), but higher than the rate of 52&#x00025; obtained in Eddy's GOG trial (quick VP regimen, intravenous vincristine 1&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and cisplatin 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> every 10 days for 3 cycles). A previous meta-analysis of <xref ref-type="bibr" rid="bib15">Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration (2003)</xref> reported that the timing and dose intensity of cisplatin-based NACT appear to have an important impact on the benefits of such treatment despite some unexplained heterogeneity between the trials in their design and results.</p><p>It is very difficult to compare the radicality of RS among trials in the Cochrane meta-analysis. Two of the trials (Napolitano's and Sardi's trials) reported markedly increased rates of radical resection with NACT, whereas no difference was found in the three trials (Cai's, Chen's, and Eddy's trials). In the present study, the rate of RS was similar in NACT group and RS group (93&#x00025;). The 5-year survival rate of patients with stage IB2 disease in the RS group of Sardi's trial was only 60&#x00025;, whereas the 4-year survival rate of patients with stage IB2 disease in the RS group of our study was 82&#x00025;. Perhaps more radical surgery eliminates the survival benefits of NACT.</p><p>Concurrent chemoradiotherapy has been considered as current standard adjuvant therapy after RS for patients with high-risk factors for recurrence since 2000 (<xref ref-type="bibr" rid="bib19">Peters <italic>et al</italic>, 2000</xref>). The role of NACT for high-risk patients who will receive chemoradiotherapy after RS is unclear. Radiotherapy alone was administered in previous NACT trials including our study. Therefore, concurrent chemoradiotherapy should be included when conducting the future NACT trial.</p><p>Optimal regimens for NACT have yet to be defined. Among the six trials included in the Cochrane meta-analysis, four trials used cisplatin-based chemotherapy combined with vincristine, three trials used bleomycin, and two trials used 5-fluorouracil or mitomycin because these trials were started between 1987 and 2001. Cisplatin-based chemotherapy combined with ifosphamide, paclitaxel, and topotecan may be more effective for cervical cancer (<xref ref-type="bibr" rid="bib17">Omura <italic>et al</italic>, 1997</xref>; <xref ref-type="bibr" rid="bib11">Moore <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="bib9">Long <italic>et al</italic>, 2005</xref>). Paclitaxel combined with cisplatin was associated with a higher response rate and better progression-free survival in patients with metastatic cervical cancer (<xref ref-type="bibr" rid="bib11">Moore <italic>et al</italic>, 2004</xref>), and one phase III trial reported that a combination of paclitaxel, cisplatin, and ifosphamide had a significantly higher response rate than cisplatin and ifosphamide (<xref ref-type="bibr" rid="bib1">Buda <italic>et al</italic>, 2005</xref>). To clarify the benefits of neoadjuvant chemotherapy, more potent regimens of chemotherapy should be explored.</p><p>In this study, the proportion of patients who received postoperative RT was significantly lower in the NACT group than in the RS group (58&#x00025; <italic>vs</italic> 80&#x00025;). In Eddy's GOG trial, the rate of postoperative RT was small, but not significantly lower in the NACT group than in the RS group (45&#x00025; <italic>vs</italic> 52&#x00025;). When we compared improvements in extrauterine pathological findings associated with NACT between these studies, the reduction in the proportion of patients with positive pelvic nodes was more apparent in the present study than in the GOG trial (from 44&#x00025; to 29&#x00025; <italic>vs</italic> from 39&#x00025; to 32&#x00025;). Improvements in other extrauterine pathological findings such as positive para-aortic nodes, parametrial involvement, and positive surgical margins were marginal in both studies. The decreased incidence of positive pelvic nodes in our trial most likely influenced the rate of postoperative RT in the NACT group.</p><p>Recently, <xref ref-type="bibr" rid="bib10">Matsumura <italic>et al</italic> (2010</xref>) reported that NACT followed by surgery plus postoperative chemotherapy with cisplatin/irnotecan or nedaplatin/irinotecan, but not RT, is a viable option for the treatment of stage IB2-IIB cervical cancer. This treatment offers the advantage of eliminating radiation-induced morbidity</p><p>In conclusion, NACT before RS did not improve overall survival in patients with stages IB2, IIA2, and IIB locally advanced cervical cancer. However, NACT did reduce the proportion of patients who received postoperative RT. Further trials are warranted to clarify the potential benefits of NACT in locally advanced cervical cancer, once new drugs or new combination regimens are shown to be effective as NACT, postoperative adjuvant chemotherapy, or both. Two ongoing randomised phase III trials (<xref ref-type="bibr" rid="bib5">EORTC 55994</xref>; <xref ref-type="bibr" rid="bib14">NCT00193739</xref>) are comparing NACT followed by surgery with concurrent chemoradiation. The results of these trials may play an important role in determining whether NACT before surgery is a valid alternative to chemoradiation.</p></sec></body><back><ack><p>We are indebted to Dr Naoki Ishizuka for the study design, Mr Takashi Asakawa for statistical support, Ms Mika Hiroo and Ms Harumi Kaba for data management, and Dr Haruhiko Fukuda for oversight of the study. This study was supported in part by the National Cancer Center Research and Development Fund (23-A-16 and 23-A-17) and by the Grants-in-Aid for Cancer Research (14S-1, 14S-4, 17S-1, 17S-5, 20S-1, 20S-6, 10&#x02013;12, 14-12) from the Ministry of Health, Labour and Welfare, Japan.</p></ack><app-group><app id="app1"><title>Appendix</title><sec><title>Institutions that participated in this study:</title><p>Hokkaido University, Sapporo Medical University, Tohoku University, Tsukuba University, Gunma Prefectural Cancer Center, National Defense Medical College, Saitama Cancer Center, Saitama Medical Center, National Cancer Center Hospital, The Jikei University Hospital, The Cancer Institute Hospital, Tokyo University, Juntendo University, Niigata Cancer Center, Nagaoka Red Cross Hospital, Shinsyu University, Aichi Cancer Center Hospital, National Hospital Organization Nagoya Medical Center, Kinki University, Osaka Medical Center for Cancer and Cardiovascular Disease, Tottori University, Kure Medical Center, Shikoku Cancer Center, National Kyushu Cancer Center, Kurume University, Kyushu University, Saga University, Kagoshima City Hospital.</p></sec></app></app-group><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn><fn><p>This study was presented in abstract form at the Annual Meeting of the American Society of Clinical Oncology, June 2006 and June 2010.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buda</surname><given-names>A</given-names></name><name><surname>Fossati</surname><given-names>R</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Fei</surname><given-names>F</given-names></name><name><surname>Floriani</surname><given-names>I</given-names></name><name><surname>Gueli Alletti</surname><given-names>D</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Landoni</surname><given-names>F</given-names></name><name><surname>Lissoni</surname><given-names>A</given-names></name><name><surname>Malzoni</surname><given-names>C</given-names></name><name><surname>Sartori</surname><given-names>E</given-names></name><name><surname>Scollo</surname><given-names>P</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><name><surname>Zola</surname><given-names>P</given-names></name><name><surname>Mangioni</surname><given-names>C</given-names></name></person-group><year>2005</year><article-title>Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study</article-title><source>J Clin Oncol</source><volume>23</volume><supplement>(18</supplement><fpage>4137</fpage><lpage>4145</lpage><pub-id pub-id-type="pmid">15961761</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>HB</given-names></name><name><surname>Chen</surname><given-names>HZ</given-names></name><name><surname>Yin</surname><given-names>HH</given-names></name></person-group><year>2006</year><article-title>Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer</article-title><source>J Obstet Gynaecol Res</source><volume>32</volume><supplement>(3</supplement><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">16764623</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year>2008</year><article-title>Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study</article-title><source>Gynecol Oncol</source><volume>110</volume><supplement>(3</supplement><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">18606439</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>GL</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Spirtos</surname><given-names>NM</given-names></name><name><surname>Mannel</surname><given-names>RS</given-names></name><name><surname>Hannigan</surname><given-names>E</given-names></name><name><surname>O'Connor</surname><given-names>D</given-names></name></person-group><year>2007</year><article-title>Treatment of (&#x0201c;bulky&#x0201d;) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group</article-title><source>Gynecol Oncol</source><volume>106</volume><supplement>(2</supplement><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">17493669</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="other">EORTC 55994. <x>
.
</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/clinicaltrials/search/view?cdrid=69375&#x00026;version=healthprofessional">http://www.cancer.gov/clinicaltrials/search/view?cdrid=69375&#x00026;version=healthprofessional</ext-link></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Yura</surname><given-names>S</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Yoshioka</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy</article-title><source>Gynecol Oncol</source><volume>107</volume><supplement>(1</supplement><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17905140</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name></person-group><year>1997</year><article-title>Interim Analysis and Data Monitoring Committee</article-title><source>Clinical Trials in Oncology,</source>1st edn, pp<fpage>80</fpage><lpage>99</lpage><publisher-name>Chapman &#x00026; Hall/CRC</publisher-name></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsumata</surname><given-names>N</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Hirakawa</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kuzuya</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Hiura</surname><given-names>M</given-names></name><name><surname>Tsunematsu</surname><given-names>R</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name></person-group><year>2006</year><article-title>Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102)</article-title><source>Proc Am Soc Clin Oncol</source><volume>24</volume><supplement>((No 18S</supplement><fpage>abstract 5013</fpage></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>HJ</given-names><suffix>3rd</suffix></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Grendys</surname><given-names>EC</given-names><suffix>Jr</suffix></name><name><surname>Benda</surname><given-names>JA</given-names></name><name><surname>McMeekin</surname><given-names>DS</given-names></name><name><surname>Sorosky</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Eaton</surname><given-names>LA</given-names></name><name><surname>Fiorica</surname><given-names>JV</given-names></name></person-group><year>2005</year><article-title>Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study</article-title><source>J Clin Oncol</source><volume>23</volume><supplement>(21</supplement><fpage>4626</fpage><lpage>4633</lpage><pub-id pub-id-type="pmid">15911865</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>M</given-names></name><name><surname>Takeshima</surname><given-names>N</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Omatsu</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Kawamata</surname><given-names>Y</given-names></name><name><surname>Umayahara</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Takizawa</surname><given-names>K</given-names></name></person-group><year>2010</year><article-title>Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy</article-title><source>Gynecol Oncol</source><volume>119</volume><supplement>(2</supplement><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">20709382</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Blessing</surname><given-names>JA</given-names></name><name><surname>McQuellon</surname><given-names>RP</given-names></name><name><surname>Thaler</surname><given-names>HT</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Benda</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Olt</surname><given-names>G</given-names></name><name><surname>King</surname><given-names>S</given-names></name><name><surname>Boggess</surname><given-names>JF</given-names></name><name><surname>Rocereto</surname><given-names>TF</given-names></name></person-group><year>2004</year><article-title>Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study</article-title><source>J Clin Oncol</source><volume>22</volume><supplement>(15</supplement><fpage>3113</fpage><lpage>3119</lpage><pub-id pub-id-type="pmid">15284262</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>U</given-names></name><name><surname>Imperato</surname><given-names>F</given-names></name><name><surname>Mossa</surname><given-names>B</given-names></name><name><surname>Framarino</surname><given-names>ML</given-names></name><name><surname>Marziani</surname><given-names>R</given-names></name><name><surname>Marzetti</surname><given-names>L</given-names></name></person-group><year>2003</year><article-title>The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb): a long-term randomized trial</article-title><source>Eur J Gynaecol Oncol</source><volume>24</volume><supplement>(1</supplement><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">12691318</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>NCCN Clinical Practice Guidelines</collab></person-group><year>2012</year><article-title>Oncology-Cervical Cancer, version I</article-title><source>National Comprehensive Cancer Network</source><x>
</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf">http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf</ext-link></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="other">NCT00193739.<x>
</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00193739?term=NCT00193739">http://clinicaltrials.gov/ct2/show/NCT00193739?term=NCT00193739</ext-link></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration</collab></person-group><year>2003</year><article-title>Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials</article-title><source>Eur J Cancer</source><volume>39</volume><supplement>(17</supplement><fpage>2470</fpage><lpage>2486</lpage><pub-id pub-id-type="pmid">14602133</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabayashi</surname><given-names>H</given-names></name></person-group><year>1921</year><article-title>Radical abdominal hysterectomy for cancer of the cervixuteri, modification of the Takayama operation</article-title><source>Surg Gynecol Obstet</source><volume>33</volume><fpage>335</fpage><lpage>341</lpage></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omura</surname><given-names>GA</given-names></name><name><surname>Blessing</surname><given-names>JA</given-names></name><name><surname>Vaccarello</surname><given-names>L</given-names></name><name><surname>Berman</surname><given-names>ML</given-names></name><name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name><name><surname>Mutch</surname><given-names>DG</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name></person-group><year>1997</year><article-title>Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study</article-title><source>J Clin Oncol</source><volume>15</volume><supplement>(1</supplement><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">8996138</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecorelli</surname><given-names>S</given-names></name><name><surname>Zigliani</surname><given-names>L</given-names></name><name><surname>Odicino</surname><given-names>F</given-names></name></person-group><year>2009</year><article-title>Revised FIGO staging for carcinoma of the cervix</article-title><source>Int J Gynaecol Obstet</source><volume>105</volume><supplement>(2</supplement><fpage>107</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">19342051</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Barrett</surname><given-names>RJ</given-names><suffix>2nd</suffix></name><name><surname>Stock</surname><given-names>RJ</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name><name><surname>Souhami</surname><given-names>L</given-names></name><name><surname>Grigsby</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Alberts</surname><given-names>DS</given-names></name></person-group><year>2000</year><article-title>Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix</article-title><source>J Clin Oncol</source><volume>18</volume><supplement>(8</supplement><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">10764420</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piver</surname><given-names>MS</given-names></name><name><surname>Rutledge</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name></person-group><year>1974</year><article-title>Five classes of extended hysterectomy for women with cervical cancer</article-title><source>Obstet Gynecol</source><volume>44</volume><supplement>(2</supplement><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">4417035</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Rydzewska</surname><given-names>L</given-names></name><name><surname>Tierney</surname><given-names>J</given-names></name><name><surname>Vale</surname><given-names>CL</given-names></name><name><surname>Symonds</surname><given-names>PR</given-names></name></person-group><year>2010</year><article-title>Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer</article-title><source>Cochrane Database Syst Rev</source><supplement>(1</supplement><fpage>CD007406</fpage><pub-id pub-id-type="pmid">20091632</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardi</surname><given-names>JE</given-names></name><name><surname>Giaroli</surname><given-names>A</given-names></name><name><surname>Sananes</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>M</given-names></name><name><surname>Soderini</surname><given-names>A</given-names></name><name><surname>Bermudez</surname><given-names>A</given-names></name><name><surname>Snaidas</surname><given-names>L</given-names></name><name><surname>Vighi</surname><given-names>S</given-names></name><name><surname>Gomez Rueda</surname><given-names>N</given-names></name><name><surname>di Paola</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results</article-title><source>Gynecol Oncol</source><volume>67</volume><supplement>(1</supplement><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">9345358</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Richter</surname><given-names>JR</given-names></name></person-group><year>1982</year><article-title>Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint</article-title><source>Biometrics</source><volume>38</volume><supplement>(1</supplement><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">7082758</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Umezawa</surname><given-names>S</given-names></name><name><surname>Ishiya</surname><given-names>T</given-names></name><name><surname>Utsugi</surname><given-names>K</given-names></name><name><surname>Hasumi</surname><given-names>K</given-names></name></person-group><year>1998</year><article-title>Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma</article-title><source>J Clin Oncol</source><volume>16</volume><supplement>(5</supplement><fpage>1869</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">9586903</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Freedman</surname><given-names>LS</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name></person-group><year>1993</year><article-title>Applying Bayesian ideas in drug development and clinical trials</article-title><source>Stat Med</source><volume>12</volume><supplement>(15-16</supplement><fpage>1501</fpage><lpage>1511</lpage>discussion 1513&#x02013;7<pub-id pub-id-type="pmid">8248659</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><year>2000</year><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><volume>92</volume><supplement>(3</supplement><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotti</surname><given-names>A</given-names></name><name><surname>Byhardt</surname><given-names>R</given-names></name><name><surname>Stetz</surname><given-names>J</given-names></name><name><surname>Gwede</surname><given-names>C</given-names></name><name><surname>Corn</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>Gunderson</surname><given-names>L</given-names></name><name><surname>McCormick</surname><given-names>B</given-names></name><name><surname>Morrisintegral</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>T</given-names></name><name><surname>Shipley</surname><given-names>W</given-names></name><name><surname>Curran</surname><given-names>W</given-names></name></person-group><year>2000</year><article-title>Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>47</volume><supplement>(1</supplement><fpage>13</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">10758303</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Trial profile.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2013179f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p><bold>Survival curves of all randomised patients.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2013179f2"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Patient characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;<hr/></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Radical hysterectomy (</bold><italic><bold>n</bold></italic><bold>=67)</bold><hr/></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Neoadjuvant chemotherapy (</bold><italic><bold>n</bold></italic><bold>=67)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Age, years</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Median</td><td colspan="2" align="center" valign="top" charoff="50">46</td><td colspan="2" align="center" valign="top" charoff="50">47</td></tr><tr><td align="left" valign="top" charoff="50">Range<hr/></td><td colspan="2" align="center" valign="top" charoff="50">22&#x02013;67<hr/></td><td colspan="2" align="center" valign="top" charoff="50">28&#x02013;70<hr/></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>ECOG performance status</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">0<hr/></td><td align="center" valign="top" charoff="50">59<hr/></td><td align="center" valign="top" charoff="50">88<hr/></td><td align="center" valign="top" charoff="50">62<hr/></td><td align="center" valign="top" charoff="50">93<hr/></td></tr><tr><td align="left" valign="top" charoff="50">1<hr/></td><td align="center" valign="top" charoff="50">8<hr/></td><td align="center" valign="top" charoff="50">12<hr/></td><td align="center" valign="top" charoff="50">5<hr/></td><td align="center" valign="top" charoff="50">8<hr/></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>FIGO stage</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">IB2<hr/></td><td align="center" valign="top" charoff="50">26<hr/></td><td align="center" valign="top" charoff="50">39<hr/></td><td align="center" valign="top" charoff="50">24<hr/></td><td align="center" valign="top" charoff="50">36<hr/></td></tr><tr><td align="left" valign="top" charoff="50">IIA<hr/></td><td align="center" valign="top" charoff="50">7<hr/></td><td align="center" valign="top" charoff="50">10<hr/></td><td align="center" valign="top" charoff="50">5<hr/></td><td align="center" valign="top" charoff="50">8<hr/></td></tr><tr><td align="left" valign="top" charoff="50">IIB<hr/></td><td align="center" valign="top" charoff="50">34<hr/></td><td align="center" valign="top" charoff="50">51<hr/></td><td align="center" valign="top" charoff="50">38<hr/></td><td align="center" valign="top" charoff="50">57<hr/></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Histology in biopsy</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Squamous cell<hr/></td><td align="center" valign="top" charoff="50">66<hr/></td><td align="center" valign="top" charoff="50">99<hr/></td><td align="center" valign="top" charoff="50">67<hr/></td><td align="center" valign="top" charoff="50">100<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Adenosquamous cell</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ECOG=Eastern Cooperative Oncology Group; FIGO=International Federation of Gynaecology and Obstetrics surgical staging system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Clinical response of neoadjuvant chemotherapy</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Response category</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Investigator assessment</bold><bold>(</bold><italic><bold>n</bold></italic><bold>=67)</bold></th><th align="left" valign="top" charoff="50"><bold>Independent central review</bold><bold>(</bold><italic><bold>n</bold></italic><bold>=67)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">CR<hr/></td><td align="char" valign="top" char="(" charoff="50">9 (13)<hr/></td><td align="left" valign="top" charoff="50">8 (12)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">PR<hr/></td><td align="char" valign="top" char="(" charoff="50">38 (57)<hr/></td><td align="left" valign="top" charoff="50">36 (54)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">SD<hr/></td><td align="char" valign="top" char="(" charoff="50">18 (27)<hr/></td><td align="left" valign="top" charoff="50">20 (30)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">PD<hr/></td><td align="char" valign="top" char="(" charoff="50">0 (0)<hr/></td><td align="left" valign="top" charoff="50">0 (0)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">NE<hr/></td><td align="char" valign="top" char="(" charoff="50">1 (1)<hr/></td><td align="left" valign="top" charoff="50">2 (3)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Overall response<hr/></td><td align="char" valign="top" char="(" charoff="50">47 (70)<hr/></td><td align="left" valign="top" charoff="50">44 (66)<hr/></td></tr><tr><td align="left" valign="top" charoff="50">95&#x00025; CI</td><td align="char" valign="top" char="(" charoff="50">58&#x02013;81</td><td align="left" valign="top" charoff="50">53&#x02013;77</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CI=confidence interval; CR=complete response; NE=not evaluable; PD=progressive disease; PR=partial response; SD=stable disease. Values are presented as <italic>n</italic> (&#x00025;).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Toxicity of chemotherapy (<italic>n</italic>=66)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3 or 4 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Leukopenia<hr/></td><td align="char" valign="top" char="." charoff="50">24<hr/></td><td align="char" valign="top" char="." charoff="50">3<hr/></td><td align="char" valign="top" char="." charoff="50">41<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia<hr/></td><td align="char" valign="top" char="." charoff="50">21<hr/></td><td align="char" valign="top" char="." charoff="50">15<hr/></td><td align="char" valign="top" char="." charoff="50">56<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Haemoglobin<hr/></td><td align="char" valign="top" char="." charoff="50">11<hr/></td><td align="char" valign="top" char="." charoff="50">5<hr/></td><td align="char" valign="top" char="." charoff="50">24<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia<hr/></td><td align="char" valign="top" char="." charoff="50">18<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">27<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Hyponatraemia<hr/></td><td align="char" valign="top" char="." charoff="50">3<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">5<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Hyperkalaemia<hr/></td><td align="char" valign="top" char="." charoff="50">1<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">2<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Nausea<hr/></td><td align="char" valign="top" char="." charoff="50">11<hr/></td><td align="center" valign="top" char="." charoff="50">&#x02014;<hr/></td><td align="char" valign="top" char="." charoff="50">17<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Vomiting<hr/></td><td align="char" valign="top" char="." charoff="50">4<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">6<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Febrile neutropenia<hr/></td><td align="char" valign="top" char="." charoff="50">2<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">3<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Fatigue<hr/></td><td align="char" valign="top" char="." charoff="50">3<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">5<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Hypersensitivity</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">3</td></tr></tbody></table></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Surgical findings</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;<hr/></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Radical hysterectomy (</bold><italic><bold>n</bold></italic><bold>=62)</bold><hr/></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Neoadjuvant chemotherapy (</bold><italic><bold>n</bold></italic><bold>=62)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Tumour diameter (cm)</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Median</td><td colspan="2" align="center" valign="top" charoff="50">5.1</td><td colspan="2" align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">Range<hr/></td><td colspan="2" align="center" valign="top" charoff="50">2.5&#x02013;13.5<hr/></td><td colspan="2" align="center" valign="top" charoff="50">0&#x02013;10.3<hr/></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><bold>Postsurgical T classification (pT)</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">0&#x02013;IB1<hr/></td><td align="center" valign="top" charoff="50">5<hr/></td><td align="center" valign="top" charoff="50">8<hr/></td><td align="center" valign="top" charoff="50">25<hr/></td><td align="center" valign="top" charoff="50">40<hr/></td></tr><tr><td align="left" valign="top" charoff="50">IB2&#x02013;pT2B<hr/></td><td align="center" valign="top" charoff="50">57<hr/></td><td align="center" valign="top" charoff="50">92<hr/></td><td align="center" valign="top" charoff="50">34<hr/></td><td align="center" valign="top" charoff="50">55<hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x0003e;2B<hr/></td><td align="center" valign="top" charoff="50">0<hr/></td><td align="center" valign="top" charoff="50">0<hr/></td><td align="center" valign="top" charoff="50">3<hr/></td><td align="center" valign="top" charoff="50">5<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Positive pelvic nodes<hr/></td><td align="center" valign="top" charoff="50">27<hr/></td><td align="center" valign="top" charoff="50">44<hr/></td><td align="center" valign="top" charoff="50">17<hr/></td><td align="center" valign="top" charoff="50">27<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Invasion to muscle layer &#x02a7e;2/3<hr/></td><td align="center" valign="top" charoff="50">52<hr/></td><td align="center" valign="top" charoff="50">84<hr/></td><td align="center" valign="top" charoff="50">38<hr/></td><td align="center" valign="top" charoff="50">61<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Parametrial invasion</td><td align="center" valign="top" charoff="50">28</td><td align="center" valign="top" charoff="50">45</td><td align="center" valign="top" charoff="50">25</td><td align="center" valign="top" charoff="50">40</td></tr></tbody></table></table-wrap><table-wrap id="tbl5"><label>Table 5</label><caption><title>Radiation morbidity</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;<hr/></th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Radical hysterectomy (</bold><italic><bold>n</bold></italic><bold>=66)</bold><hr/></th><th colspan="3" align="center" valign="top" char="." charoff="50"><bold>Neoadjuvant chemotherapy (</bold><italic><bold>n</bold></italic><bold>=67)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3 or 4 (&#x00025;)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Grade 3 or 4 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50"><bold>Early adverse events</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Leukocytes</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Haemoglobin</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytes</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">Nausea</td><td align="char" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Vomiting</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Lymphedema</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Dysuria</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Urinary retention<hr/></td><td align="char" valign="top" char="." charoff="50">9<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">14<hr/></td><td align="char" valign="top" char="." charoff="50">5<hr/></td><td align="char" valign="top" char="." charoff="50">0<hr/></td><td align="char" valign="top" char="." charoff="50">7<hr/></td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><bold>Late adverse events<xref ref-type="fn" rid="t5-fn1">a</xref></bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Lymphedema</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">Urinary retention</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">11</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">Vesicovaginal fistula</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">Bowel obstruction</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">4</td></tr></tbody></table><table-wrap-foot><fn id="t5-fn1"><label>a</label><p>Late adverse events were defined as the adverse events that were observed more than 90 days after radiation therapy.</p></fn></table-wrap-foot></table-wrap></floats-group></article>